Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Vaxzevria is Highly Effective After One Dose Against Severe Disease or Hospitalisation Caused by Beta and Delta Variants of Concern
Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of […]
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for […]
Oxford/AstraZeneca Alternative Now Available at Riverside Vaccination Centre
Vaccination appointments are available for residents who are eligible at the Riverside Vaccination Centre in […]
‘We Can Treat It’: Mortality Rate of Rare Condition Linked to AstraZeneca Shot Plunges
Doctors are now confident they can detect and treat the rare blood clotting syndrome associated […]
Calquence Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients with Chronic Lymphocytic Leukaemia and Sustained Patient Benefit at Four Years in the Front-line Setting
Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior […]
Tagrisso Approved in the EU for the Adjuvant Treatment of Patients with Early-stage EGFR-mutated Lung Cancer
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult […]
Drug Discovery Gets Jolt of AI via NVIDIA Collaborations with AstraZeneca, U of Florida Health
NVIDIA is collaborating with biopharmaceutical company AstraZeneca and the University of Florida’s academic health center, […]
Amgen Tezepelumab BLA Submitted to U.S. FDA
Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to […]
UK Medicines Regulator Issues its First Authorisation Under Project Orbis
A post-surgery treatment for lung cancer will be the first to receive an authorisation from […]
Imfinzi, Tremelimumab and Chemotherapy Demonstrated Significant Benefit Versus Chemotherapy Alone
POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more